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In the absence of repair mechanisms involving angio-
genesis and cardiomyogenesis, loss of cardiomyocytes 
after myocardial injury is a primary causative factor in the 
progression toward heart failure. In an effort to reduce 
ischemic myocardial damage, we investigated the effects 
on infarcted myocardium of transplantation of geneti-
cally modified mesenchymal stem cells (MSCs) that spe-
cifically expressed vascular endothelial growth factor 
(VEGF) under hypoxic conditions. A hypoxia-inducible 
VEGF expression vector was introduced into MSCs (HI-
VEGF-MSCs) using a nonviral delivery method, which 
were then used for the treatment of ischemic myocardial 
injury in rats. In HI-VEGF-MSCs, VEGF expression was 
significantly increased by hypoxia in vitro as compared 
to normoxia. Likewise, in vivo administration of HI-VEGF-
MSCs induced ischemia-responsive VEGF production, 
leading to a significant increase in myocardial neovas-
cularization after myocardial infarction. When compared 
with unmodified-MSCs, HI-VEGF-MSCs were retained in 
infarcted myocardium in greater numbers and remark-
ably reduced the number of apoptotic cells the infarcted 
area. Transplantation of HI-VEGF-MSCs resulted in a sub-
stantial attenuation of left ventricular remodeling in rat 
myocardial infarction. This study demonstrates that cell-
based gene therapy using genetically engineered MSCs 
to express VEGF in response to hypoxic stress can be 
a promising therapeutic strategy for the treatment of 
 ischemic heart disease.
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IntroductIon
Despite rapid advances in the medical treatment of cardiometa-
bolic risk factors, cardiovascular disease remains the leading cause 
of morbidity and mortality in the world.1 Since adult hearts have 
a limited capacity for regeneration, stem cell-based approaches 
for cardiac repair following myocardial infarction have been 
investigated and show considerable promise in reducing myo-
cardial infarct size and improving cardiac function.2 Recently, 
bone marrow-derived mesenchymal stem cells (MSCs) have 
attracted attention as an excellent model for development of cell-
based therapeutics due to their potential for repairing damaged 
tissue.3 In particular, MSCs possess many advantageous cellular 
attributes, such as ease of isolation, high expansion potential, 
genetic  stability, and multipotential differentiation capacity.4 For 
these reasons, MSCs have emerged as the most suitable candi-
dates for use in cellular therapy and tissue engineering. Several 
preclinical studies have reported that MSCs positively modulate 
deleterious ventricular remodeling and improve recovery of car-
diac performance after myocardial infarction,5 although the exact 
repair mechanisms behind these effects have not yet been eluci-
dated. Restoration of cardiac function after myocardial infarction 
requires not only replacement of lost cardiomyocytes but also 
neovascularization of ischemic myocardium. Emerging evidence 
suggests that MSCs are capable of regenerating both blood ves-
sels and myocardium damaged after myocardial infarction.4,6 
Further, experimental studies evaluating the histological localiza-
tion of MSCs have reported that a majority of engrafted MSCs 
are positive for cardiomyocyte-specific marker proteins, and that 
a  distinct sub-population of transplanted cells are incorporated 
into microvessels at sites of revascularization.7
In spite of widespread interest in MSCs, an optimal approach 
for MSC-based tissue repair and regeneration has not been estab-
lished. Indeed, poor viability and limited incorporation into target 
tissues are major drawbacks to achieving long-term therapeutic 
success in MSC therapy. Based on the research used to quantify 
the degree of MSC engraftment in ischemic myocardium, the 
survival rate of transplanted mouse MSCs is thought to be <1% 
at day 4 postimplantation.4 Although administration of a higher 
number of cells can provide a small augmentation with respect 
to long-term engraftment, intact MSCs transplantation itself is 
not sufficient to alleviate progressive deterioration in myocardial 
function. To overcome these issues, cell therapy using genetically 
engineered cells has been suggested as an effective strategy to 
improve the survival rate and therapeutic efficacy of MSCs.8–10 In 
addition to therapeutic applications in tissue regeneration, MSCs 
may also be useful as vehicles for in vivo gene delivery owing to 
their good genetic stability. After transfection with exogenous 
genes using various gene carriers, MSCs can sustain stable and 
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long-term transgene expression without genetic modification even 
after in vivo differentiation.11 Thus, MSC-mediated gene therapy 
has been investigated as an attractive option for the treatment of 
numerous diseases including myocardial infarction.
Gene therapy with angiogenic factors holds great promise in 
the treatment of ischemic diseases due to its ability to promote neo-
vascularization.12 In particular, vascular endothelial growth factor 
(VEGF), one of the most potent angiogenic factors, is capable of 
actively affecting both angiogenesis and myogenesis in cardiac 
injury repair.13 More recent works have shown that VEGF treat-
ment leads to enhancement of MSC viability in infarcted hearts 
by reducing cellular stress and increasing cell survival factors.14,15 
Thus, it is anticipated that cell therapy using genetically modified 
MSCs expressing VEGF may offer a potentially valuable approach 
for the treatment of myocardial infarction due to enhanced sur-
vival and angiogenic capacity. In our recent studies, we have 
constructed different types of hypoxia-specific VEGF expression 
systems and have used them as effective gene therapy strategies for 
salvaging myocardial ischemia and infarction due to their abilities 
to precisely controlled VEGF expression in the regions of isch-
emia.16–19 Considering these findings, we hypothesized that the 
combination of two promising strategies, MSC transplantation 
and ischemia-inducible VEGF gene transfer, could induce success-
ful MSC engraftment in ischemic myocardium through localized 
enhancement of VEGF levels, thereby maximizing their respective 
therapeutic potentials. In this study, we genetically modified 
rat MSCs using a hypoxia-inducible VEGF plasmid (pEpo-SV-
VEGF). We then used these cells, which had enhanced cell sur-
vival, to promote angiogenesis in order to more effectively repair 
infarcted rat myocardium. We expected the hypoxia-inducible 
VEGF-engineered MSCs (HI-VEGF-MSCs) to overexpress VEGF 
specifically under ischemic conditions in order to provide valu-
able therapeutic benefits in vivo. We examined in vitro gene trans-
fection efficiencies in rat MSCs with various nonviral carriers and 
VEGF plasmids to optimize the preparation of HI-VEGF-MSCs 
and then evaluated the therapeutic potentials of HI-VEGF-MSCs 
in vivo using a rat myocardial infarction model.
results
Preparation and characterization of HI-VeGF-Mscs
In vitro transfection and cell viability assay. In primary cul-
tured cells including bone-marrow-derived MSCs, most transfec-
tion techniques achieve very low efficiencies, generally no more 
than a few percent. Thus, preparing effective transfection meth-
odologies is crucial to the success of MSC-based gene therapy.20,21 
In order to provide optimal transfection efficiency in MSCs, com-
monly used nonviral transfection methods were evaluated in rat 
MSCs using pCMV-Luc as a reporter gene (Figure 1). Although 
genetic modification has been performed mainly using viral tech-
























































































Figure 1 Plasmid transfection efficiency in mesenchymal stem cells (Mscs) using nonviral transfection reagents. (a) Selection of transfection 
reagent providing the best efficiency among conventional nonviral gene delivery vectors. pCMV-Luc plasmid (pDNA concentration = 0.2 µg/ml) was 
transfected into rat MSCs with branched poly(ethylenimine) (BPEI, 25 kDa), linear PEI (LPEI, 25 kDa), dexamethasone-conjugated BPEI (PEI-Dexa, 
2 kDa), and Lipofectamine (Lipof) at transfection reagent-to-pDNA weight ratios of 1, 1, 8, and 12, respectively. *P < 0.05 versus LPEI. (b) Luciferase 
expressions in MSCs transfected by pCMV-Luc (pDNA concentration = 0.2 µg/ml) condensed with LPEI at various N/P (nitrogen of PEI/phosphate of 
DNA) ratios ranging from 1 to 15 (weight ratio from 0.1 to 2.0). *P < 0.05. (c) Cellular toxicities of LPEI/pDNA complexes prepared at various N/P 
ratios ranging from 3 to 20 in MSCs. *P < 0.05 versus N/P ratio of 3. RLU, relative light unit; ns, not significant.
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insertional mutagenesis and immune response caused by viral 
vectors.22 Four nonviral gene transfection reagents, branched 
poly(ethylenimine) (BPEI), linear PEI (LPEI), dexamethasone-
conjugated PEI, and Lipofectamine, were examined in order to 
identify the best reagent for MSCs in terms of eliciting the  highest 
transfection efficiency possible (Figure 1a). Branched PEI is the 
most widely studied nonviral gene transfer method despite its 
relatively high cytotoxicity.23 Although LPEI shows slightly low 
transfection efficiency in some commonly used cell lines, it can be 
used as an alternative transfection method owing to the extreme-
ly low  cytotoxicity.23 Dexamethasone-conjugated PEI has been 
used previously to enhance the transfection efficiency of normal 
and cancer cell lines due to its high potency for translocation of 
 polymer/pDNA complexes into the nucleus.24
Among the four nonviral vectors described above, LPEI 
exhibited the highest luciferase activity in rat MSCs, nearly 
twofold higher than that of the commercial transfection agent 
lipofectamine, which produced the second highest transfec-
tion efficiency. Based on this result, LPEI was used as the trans-
fection reagent for MSCs in further experiments. To optimize 
the high-efficiency transfection methodology for low passage 
MSCs derived from rat bone marrow, the transfection efficien-
cies and cytotoxicities of polymer/pDNA complexes were esti-
mated at varying mixing ratios of LPEI to pDNA (Figure 1b,c). 
Transfection efficiencies gradually increased with an increasing 
N/P ratio (nitrogen of PEI/phosphate of DNA), which plateaued 
at a N/P ratio of 10. Enhancement in gene expression was accom-
panied by a corresponding decrease in cellular viability; however, 
cytotoxicity was not observed up to a N/P ratio of 10. Thus, on the 
basis of these in vitro transfection results, the optimized transfec-
tion condition consisting of LPEI at a N/P ratio of 10 was used in 
the following experiments to evaluate the therapeutic potentials of 
HI-VEGF-MSCs both in vitro and in vivo.
In vitro VEGF expression under hypoxia. Levels of VEGF 
 expression in genetically engineered MSCs under hypoxic condi-
tions were examined using three different candidates for hypoxia-
inducible VEGF plasmids (Figure 2a). Specifically, pSG5-VEGF, 
pRTP801-VEGF, and pEpo-SV-VEGF were transfected into MSCs, 
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Figure 2 Preparation of hypoxia-inducible vascular endothelial growth factor-engineered mesenchymal stem cells (HI-VeGF-Mscs). 
(a) Schematic representation of the different types of hypoxia-inducible VEGF expression vector constructs. (b) Selection of hypoxia-inducible VEGF 
plasmid having the highest gene expression efficiency in MSCs. Each VEGF expression vector was transfected into MSCs with linear poly(ethylenimine) 
(N/P (nitrogen of PEI/phosphate of DNA) ratio = 10). After transfection, cells were incubated in hypoxic conditions for 1 day, and the amount of 
secreted VEGF in the culture supernatant was determined with enzyme-linked immunosorbent assay (ELISA). *P < 0.05 versus pEpo-SV-VEGF. (c) Level 
of VEGF expression in HI-VEGF-MSCs under normoxia and hypoxia. pEpo-SV-VEGF was transfected into MSCs with LPEI (N/P ratio = 10). After trans-
fection, cells were further incubated in normoxic or hypoxic conditions for the desired time period. The VEGF concentration of each conditioned 
medium was measured using ELISA. *P < 0.05 versus normoxia; **P < 0.01 versus normoxia. (d) Phenotypic analysis of MSCs surface markers. MSCs 
and HI-VEGF-MSCs were stained for different selectable markers (positive: CD90 (red), negative: CD45 (blue) and CD34 (green)). An unstained MSCs 
sample was used as a negative control (black). M1 refers to the gated area (fluorescence intensity (arbitrary unit): 101–104). ns, not significant.
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simian virus 40 (SV40) enhancer-promoter, RTP801 promoter, 
and erythropoietin enhancer-SV40 promoter were previously 
developed to induce target gene expression at the transcriptional 
level in response to hypoxic stresses in vitro and in vivo.16,18 Of 
the three hypoxia-inducible VEGF expression vectors, pEpo-SV-
VEGF showed the highest level of VEGF expression in MSCs un-
der both hypoxia and normoxia (data not shown). Although intact 
MSCs are known to produce VEGF under normoxic and hypoxic 
conditions,25 the VEGF levels in plain MSCs fall below the range 
of detection by an enzyme-linked immunosorbent assay (ELISA) 
kit in both normoxia and hypoxia (data not shown). Based on 
the potency in activating hypoxic gene expression, the pEpo-SV-
VEGF vector was used to generate HI-VEGF-MSCs for further 
in vivo applications. In order to assess the impact of persistent 
hypoxic exposure on VEGF gene expression levels in MSCs, the 
pEpo-SV-VEGF-transfected MSCs were incubated  under  hypoxia 
and normoxia for the desired period of time from 2 to 14 days 
(Figure 2c). When pEpo-SV-VEGF-transfected MSCs were ex-
posed to hypoxic conditions, cells maintained a constant and high 
level of VEGF expression compared to those of cells incubated in 
normoxia. The elevated levels of VEGF expression in HI-VEGF-
MSCs lasted at least 2 weeks. It is generally accepted that nonviral 
vector-mediated transient transgene expression can be sustained 
for up to 4 weeks in primary cells.26 In addition, previous stud-
ies have reported that VEGF-engineered MSCs increased VEGF 
induction within 1 day after transplantation on ischemic myo-
cardium and the enhancement was maintained until 1 to 2 weeks 
and then disappeared. These prompted us to estimate the in vivo 
therapeutic effectiveness of HI-VEGF-MSCs in rat ischemic myo-
cardium 2 weeks postimplantation. Importantly, as shown in 
Figure 2d, the expression pattern of MSCs surface markers did 
not change after pEpo-SV-VEGF modification.
In vivo HI-VeGF-Msc transplantation in ischemic 
myocardium
In vivo VEGF expression. To estimate whether HI-VEGF-MSCs 
expressed VEGF in response to ischemia in vivo, myocardial 
VEGF levels after cell transplantation were analyzed in  normal 
and left anterior descending coronary artery (LAD)-ligated 
 animals (Figure 3). In normal heart samples, VEGF expression 
in HI-VEGF-MSC-transplanted groups (54.5 ± 25.4 pg/g of pro-
tein) was maintained at levels similar to that of the control group 
(58.5 ± 60.7 pg/g of protein). It is particularly interesting to note 
that the HI-VEGF-MSCs transplantation (257.7 ± 67.4 pg/g of 
protein) showed ~1.4-fold increase in VEGF production in LAD-
ligated hearts compared with that of saline treatment (191.1 ± 
31.2 pg/g of protein), in good agreement with our in vitro trans-
fection experiments. Unfortunately, serum VEGF levels were 
 below the range of detection using an ELISA kit in both the nor-



























Figure 3 In vivo vascular endothelial growth factor (VeGF) expression 
levels of hypoxia-inducible-VeGF-engineered mesenchymal stem cells 
(HI-VeGF-Mscs) in normal and ischemic myocardium. HI-VEGF-MSCs 
were transplanted into myocardium with/without left anterior descend-
ing coronary artery-ligation (n = 10/group). Control groups received 
saline injections (n = 6/group). Tissue samples were collected 2 days after 
transplantation and were analyzed by enzyme-linked immunosorbent 




























Figure 4 engraftment efficiencies of hypoxia-inducible vascular endothelial growth factor-engineered mesenchymal stem cells (HI-VeGF-
Mscs) within ischemic myocardium. (a) Representative hematoxylin and eosin (H&E, left panel, ×100) and 4’,6-diamidino-2-phenylindole (DAPI, 
right panel, ×400) stained myocardial sections. Tissue samples were obtained from left anterior descending coronary artery (LAD)-ligated rats 3 days 
after injection of MSCs and HI-VEGF-MSCs. The presence of transplanted MSCs was recognized by blue fluorescence signals generated by DAPI (white 
arrow). Bars: black = 500 µm, white = 100 µm. (b) Comparison of engraftment levels of MSCs and HI-VEGF-MSCs in ischemic myocardium (n = 6/
group). *P < 0.01. (c) Immunostaining of human VEGF. Tissue samples were obtained from LAD-ligated rats at 2 days after transplantation and were 
stained with antihuman VEGF antibodies. ×100 magnification, Bar = 500 µm.
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due to the rapid diffusion of secreted VEGF into the serum in 
high-dilution conditions.
MSC engraftment and human VEGF expression. For  histological 
tracking of implanted MSCs, the presence of 4′,6-diamidino-2-
phenylindole (DAPI)-labeled MSCs and HI-VEGF-MSCs were 
analyzed after experimentally induced myocardial infarction 
in rats (Figure 4c,d). Upon injection of unmodified MSCs into 
the infarcted heart, only a few DAPI-positive cells were detected 
in the infarcted area 3 days postimplantation; however, when 
HI-VEGF-MSCs were injected, there was a marked increase in 
the number of DAPI-positive cells. As shown in Figure 4b, the 
achieved engraftment efficiencies of MSCs and HI-VEGF-MSCs 
were 5.0 ± 2.6 and 58.3 ± 16.2 cells per section, respectively. In 
general, the number of engrafted MSCs is reported to be virtually 
diminished within 3–5 days after implantation.27 In particular, 
HI-VEGF-MSC-transplanted rat myocardium exhibited a dis-
tinct immuno-reactivity against the antihuman VEGF antibody 
(Figure 4c), suggesting that the HI-VEGF-MSC engraftment can 
provide additional human VEGF as well as rat VEGF induced by 
myocardial ischemia in rats (Figure 3).
Neovascularization. To examine the density of capillaries in 
the infarcted heart after cell transplantation, immunostaining of 
micro-vessels using a CD31 antibody was performed for ischemic 
rat myocardium 2 weeks post-transplantation (Figure 5a,b). As 
compared to saline and intact MSC-injected groups, HI-VEGF-
MSC-transplanted groups exhibited a significant increase in 
 microvascularization of the infarcted myocardial tissues. The 
mean number of CD31-positive cells per square millimeter of 
 infarct was also quantified as shown in Figure 5b. Specifically, 
the micro-vessel densities in the infarcted myocardia treated with 
 saline, MSCs, and HI-VEGF-MSCs were 75.0 ± 33.7, 157.9 ± 59.4, 
and 631.1 ± 171.3 CD31+ cells/mm2, respectively. The increase 
in vessel density appeared to be the result of VEGF induction in 
 hypoxic MSCs, which is consistent with the expectation that high 
VEGF production may promote neoangiogenesis.28
Antiapoptotic effects in ischemic myocardium. To investigate 
the effect of cell transplantation on apoptotic cell death in the areas 
adjacent to the infarction, sections from saline-, MSC-, and HI-
VEGF-MSC-treated hearts were processed for terminal deoxynu-
cleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) 
assay 2 weeks following LAD-ligation (Figure 5c,d). The degree 
of apoptosis was quantified by counting the number of TUNEL-
positive cells in the sections (Figure 5d). The extent of TUNEL-
positive apoptotic cell death was greatly increased after LAD-
ligation (57.3 ± 10.3 TUNEL+ cells/high power fields (HPF)). 
Both MSC-based treatments resulted in a trend toward reduction 
in apoptosis in the infarcted myocardium. Specifically, compared 
with the LAD-ligation group, intact MSC transplantation showed 
only 2.7-fold reduced induction of apoptosis (21.5 ± 5.4 TUNEL+ 
cells/HPF), while ischemia-induced apoptotic cell death was 
 attenuated up to 13.9-fold through HI-VEGF-MSC transplanta-
tion into infarcted myocardium (4.1 ± 0.5 TUNEL+ cells/HPF). 



















































Figure 5 effects of hypoxia-inducible vascular endothelial growth factor-engineered mesenchymal stem cell (HI-VeGF-Msc) transplantation 
on neovascular formation and apoptosis in ischemic myocardium. (a) Representative images of myocardial sections stained for CD31 (×100). 
Rat ischemic myocardia were injected with saline, MSCs, or HI-VEGF-MSCs. Normal refers to sham-operated myocardium. Tissue samples were 
collected 2 weeks after transplantation and were immunostained with anti-CD31. Bar = 500 µm. (b) Extent of capillary tube formation in ischemic 
myocardia treated with saline, MSCs, or HI-VEGF-MSCs (n = 6/group). *P < 0.01. (c) Representative micrographs of terminal deoxynucleotidyl 
transferase- mediated dUTP nick-end labeling (TUNEL)-stained ischemic myocardium (×400). Rat hearts treated with saline, MSCs, and HI-VEGF-MSCs 
were stained with TUNEL reagents 2 weeks after transplantation. Bar = 100 µm. (d) Levels of apoptosis in ischemic myocardium treated with saline, 
MSCs, or HI-VEGF-MSCs (n = 6/group). *P < 0.01; HPF, high-power field.
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by HI-VEGF-MSCs may have enhanced the ability to inhibit 
 ischemia-induced apoptosis in myocardium after infarction.
Fibrosis and infarct size. The extent of cardiac fibrosis was 
 assessed by staining collagen-containing fibers in rat myocardial 
tissue using Masson’s trichrome. Figure 6a shows representative 
photographs of the longitudinal section of the heart 2 weeks follow-
ing sham operation or LAD-ligation with/without cell transplan-
tation. As shown in Figure 6b, the improvement in cardiac fibro-
sis was quite remarkable in HI-VEGF-MSC-transplanted groups 
(9.2 ± 4.1%) compared to those of the saline- and MSC-injected 
groups (32.5 ± 9.8 and 16.7 ± 3.2%, respectively). As shown by 
the representative photographs in Figure 6c, the infarcted fibrotic 
tissue appeared as a pale yellow color. Both MSC and HI-VEGF-
MSC transplantations led to decrease in infarct size compared with 
that of the saline-treated control group. Infarct size was quantita-
tively assessed by measuring the ratio of infarcted myocardium in 
the left ventricle (Figure 6d). The degree of infarct expansion was 
 approximately twofold lower in the HI-VEGF-MSC-transplanted 
animals (1.8 ± 0.3%) than it was in the unmodified MSC-treated 
animals (3.9 ± 1.1%), suggesting that the improved therapeutic 
 effects of HI-VEGF-MSCs could be caused by their augmented 
neovascularization and cell survival, as observed above.
Cardiac function. To investigate the cardiac functional improve-
ment of ischemic myocardium with HI-VEGF-MSC treatment, 
transthoracic echocardiography was performed at baseline and 
for saline-, MSC-, and HI-VEGF-MSC-transplanted rat  ischemic 
myocardium (Figure 7). Two weeks after LAD-ligation, both 
MSC and HI-VEGF-MSC treatments improved cardiac function 
compared with the saline-injected groups (27.6 ± 6.5 and 32.2 ± 
10.0% fractional shortening, and 50.7 ± 8.7 and 64.4 ± 16.9% ejec-
tion fraction, respectively). Although HI-VEGF-MSCs exhibited 
a higher level of myocardial functional recovery than MSCs, their 
enhancement of systolic performance was insufficient to show a 
statistically significant benefit in left ventricular functional per-
formance at 2 weeks after LAD ligation.
dIscussIon
Myocardial infarction frequently leads to deleterious remodel-
ing of myocardium resulting in severe ventricular dysfunction.4 























































Figure 6 effects of hypoxia-inducible vascular endothelial growth factor-engineered mesenchymal stem cell (HI-VeGF-Msc) transplantation on 
left ventricular fibrosis and infarct size after myocardial ischemia. (a) Representative histological sections of rat myocardium stained with Masson’s 
trichrome (lower panel: ×200). Rat ischemic myocardia were injected by saline, MSCs, or HI-VEGF-MSCs. Normal refers to sham-operated myocardium. 
Tissue samples were collected 2 weeks after transplantation and were stained with hematoxylin and eosin and Masson’s trichrome. Bar = 200 µm. 
(b) Percent fibrosis (myocardial collagen) expressed as the ratio of fibrotic area to left ventricle area in left anterior descending coronary artery (LAD)-
ligated rats treated with saline, MSCs, or HI-VEGF-MSCs injections (n = 6/group). *P < 0.05. (c) Representative 2, 3, 5-triphenyltetrazolium chloride-
stained sections of rat hearts (with/without LAD-ligation) with saline-, MSC-, or HI-VEGF-MSC-treatments. (d) Percentage of the ratio of infarcted to 
noninfarcted left ventricular myocardium from LAD-ligated rats treated with saline, MSCs, or HI-VEGF-MSCs (n = 6/group). *P < 0.01. LV, left ventricle.
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approaches using autologous stem cells have been tested as a 
means to minimize myocardial ischemia.2 Transplantation of 
bone marrow-derived MSCs has been shown to be effective in 
attenuating deleterious ventricular remodeling and improving 
cardiac performance after myocardial infarction.29,30 However, 
MSC-based therapeutic strategies have achieved limited success 
in repairing damaged myocardium because of poor cell  viability 
and low cell retention. Several recent reports have indicated that 
exogenous supplementation of angiogenic molecules such as 
VEGF and insulin-like growth factor 1 promotes MSC retention 
and growth in the myocardium after transplantation,14,31 which 
are needed for successful long-term cardiac regeneration. In addi-
tion to their important role in enhancing the survival of MSCs, 
therapeutic angiogenesis induced by angiogenic factors has great 
potential in the prevention and treatment of ischemic heart dis-
ease. Accordingly, combining MSCs and angiogenic factors may 
provide a valuable therapeutic approach to improve the efficacy of 
cell-based treatments.
This study aimed to evaluate the effects of HI-VEGF-MSC 
transplantation on vascular regeneration and cardioprotection in 
a rat myocardial infarction model. In our recent studies,  several 
hypoxia-specific VEGF expression systems were designed to be 
used as potential candidates for gene therapy in the treatment of 
ischemic limb and heart disease.16–19 In order to facilitate VEGF 
production in MSCs especially under ischemic conditions, here in 
rat MSCs were genetically modified by transfection with a hypoxia-
inducible VEGF plasmid (pEpo-SV-VEGF) using LPEI as a nonvi-
ral vector. There were no phenotypic changes in MSCs upon the 
hypoxia-inducible VEGF plasmid modification, which was deter-
mined by observing no marked differences in the expression pat-
terns of positive (CD90) and negative (CD34 and CD45) selectable 
markers in MSCs after genetic modification (Figure 2d). Previous 
studies revealed that genetically engineered MSCs can maintain 
transgene expression without genetic modification in vitro and in 
vivo.11 This genetic stability is one of the positive attributes of MSCs 
for development of cell-mediated gene therapy.
Both in vitro and in vivo exposures to hypoxic conditions dis-
played significantly higher levels of VEGF expression in HI-VEGF-
MSCs compared to those experiencing normoxia (Figures 2 and 3). 
It should be noted that the transplantation of HI-VEGF-MSCs 
into normal heart sustained a low level of VEGF within the nor-
mal range. Thus, it was expected that the therapeutic approaches 
using HI-VEGF-MSCs would alleviate the safety  concerns for 
VEGF-based therapeutics, such as risk of disease progression and 
mortality in cancer patients. Moreover, the control group with 
saline injection exhibited somewhat higher VEGF levels after 
LAD-ligation, indicating that hypoxia alone could induce VEGF 
production and angiogenesis in ischemic myocardia. It is well 
known that the local levels of VEGF temporarily increase in isch-
emic regions in order to support the body’s defense mechanisms 
against further ischemia-reperfusion injury.32 However, this slight 
increase in VEGF production in the ischemic heart is not sufficient 
to promote neovascularization or to attenuate myocardial ischemic 
injury through VEGF-induced angiogenic activities.33
Notably, the use of HI-VEGF-MSCs was able to promote 
transplanted cell retention and survival within the infarcted myo-
cardium compared with that of unmodified MSCs (Figure 4c,d). 
In general, intact MSCs show no engraftment or only very low 
level engraftment. Several lines of experimental evidence have 
indicated that >97% of MSCs administered via direct intramus-
cular injection are typically eliminated from an infarct region 
after 2 weeks.4 However, recent studies have revealed that engi-
neered cells displaying increased VEGF levels exhibit enhanced 
cell survival and engraftment following injection into the target 
tissues compared to those of cells expressing low levels of VEGF. 
For instance, transplantation of VEGF-engineered myoblasts into 
mouse muscle led to increased VEGF levels and cell viability, 
resulting in improvements in skeletal muscle repair.34,35 Therefore, 
it is conceivable that the increased cell survival rate of HI-VEGF-
MSCs could be attributed to their remarkable induction of VEGF 
expression in response to ischemia. More recent studies have 
suggested that cardiac cell therapy provides therapeutic benefits 
mainly through the paracrine actions of factors released by trans-
planted cells, rather than by direct regeneration.36,37
It is interesting that transplantation of HI-VEGF-MSCs 















































Figure 7 effects of hypoxia-inducible vascular endothelial growth factor-engineered mesenchymal stem cell (HI-VeGF-Msc) transplantation 
on left ventricular function. (a) Left ventricular fractional shortening and (b) ejection fraction. Rat ischemic myocardia were injected by saline, 
MSCs, or HI-VEGF-MSCs (n = 6/group). Normal refers to sham-operated myocardium. Cardiac functions were assessed by transthoracic echocardio-
graphy 2 weeks after left anterior descending coronary artery (LAD) ligation. *P < 0.05; **P < 0.01.
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region adjacent to the infarct myocardium (Figure 5a,b). This 
effect was most likely due to expression of high levels of VEGF 
mediated by ischemic stress, consistent with the findings of a pre-
vious studies demonstrating that VEGF prevents stress-induced 
apoptosis of muscle and endothelial cells.38 Further, it has been 
observed that intramuscular administration of VEGF protein 
leads to reduced apoptosis in ischemic mouse skeletal muscle 
compared to that of control mice that did not receive VEGF.39 
In particular, engrafted HI-VEGF-MSCs dramatically promoted 
micro-vessel formation in rat myocardium after LAD-ligation 
(Figure 5c,d), mainly due to VEGF-induced capillary angiogen-
esis. In addition to their angiogenic effects, the use of HI-VEGF-
MSCs was expected to provide myocardial protection against 
ischemic injury. It has been previously reported that the reduc-
tion in postmyocardial infarction remodeling is accompanied by 
an increased capillary density induced by VEGF.40 Thus, VEGF 
induction by HI-VEGF-MSCs may contribute to increased capil-
lary density in ischemic hearts, resulting in a remarkable reduc-
tion in infarct extension and fibrotic tissue formation (Figure 6). 
Since the extent of cardiomyocyte differentiation of transplanted 
stem cells was relatively meager, improvement in cardiac function 
from MSC therapy after myocardial infarction may not have been 
due to a significant replacement of lost cells. The augmentation of 
cardioprotective effects of HI-VEGF-MSC transplantation could 
be attributed to angiogenic and paracrine effects rather than direct 
replacement of lost cardiomyocytes from MSCs. Unfortunately, 
these robust enhancements of HI-VEGF-MSC treatment in vari-
ous histologic findings were insufficient to show a statistically sig-
nificant difference in cardiac functional performance, although rat 
ischemic myocardium injected with HI-VEGF-MSCs displayed a 
higher functional recovery compared to that injected by MSCs 
alone (Figure 7). It is probably due to the lack of an appropriate 
VEGF plasmid delivery system for primary cells such as MSCs. 
Since the therapeutic efficiency of genetically engineered cells 
mainly depends on the gene delivery vectors,41 the development 
of technologies for efficient delivery of therapeutic genes into 
MSCs may provide more functional benefits. For potential clinical 
application of HI-VEGF-MSCs, use of enhancing gene delivery 
reagents need to be further considered.
In conclusion, we have demonstrated a new approach to cell-
based gene therapy using MSCs generically engineered to over-
express VEGF under hypoxia for the treatment of myocardial 
infarction in rats. The transplantation of HI-VEGF-MSCs was 
able to enhance neovascularization, while simultaneously reduc-
ing apoptosis in infarcted myocardium through VEGF induction 
in response to ischemia. The enhanced and prolonged efficacy 
of MSC-based gene therapy using HI-VEGF-MSCs may provide 
beneficial effects in the attenuation of infarct expansion and the 
preservation of left ventricle area after myocardial infarction. 
Therefore, HI-VEGF-MSC transplantation may offer potential 
for a novel therapeutic strategy for the treatment of a number 
of clinical disorders related to ischemia-induced tissue injury, 
including stroke, coronary artery disease, and peripheral artery 
disease. Since the insufficient myocardial functional recovery of 
HI-VEGF-MSC treatment may restrict its clinical application, use 
of potential gene delivery systems should be further considered to 
provide optimal VEGF-engineered cells.
MaterIals and MetHods
Animals. Sprague–Dawley rats were obtained from Samtako Bio (Osan, 
Korea). The use of animals was in accordance with the International Guide 
for the Care and Use of Laboratory Animals. The experimental protocol 
was approved by the Animal Research Committee of Yonsei University 
College of Medicine.
MSC isolation and culture. Four-week-old male Sprague–Dawley rats 
(100 ± 5 g) were used for MSC isolation. MSCs were harvested, propa-
gated, and characterized as described previously.42,43 Briefly, rat bone 
marrow- derived cells were flushed out from femurs and tibias with culture 
medium. Mononuclear cells were isolated by Ficoll-Paque density gradient 
centrifugation (Amersham Biosciences, Uppsala, Sweden). After 48 hours 
incubation, nonadherent cells were discarded, and adherent cells were fur-
ther expanded until confluent. MSCs were cultured in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal bovine serum and 1% peni-
cillin-streptomycin up to 80% confluency for three or four passages before 
their use in vitro and in vivo. In order to verify that the isolated cells were 
phenotypically MSCs, the cultured cells were labeled against various cell-
surface markers characteristic for MSCs and analyzed by flow cytometry.
DNA construction. pCMV-Luc was constructed by inserting the firefly 
luciferase cDNA fragment from pGL3-control vector (Promega, Madison, 
WI) into the HindIII/XbaI sites of pcDNA3 (Invitrogen, Carlsbad, CA).44 
Since human VEGF165 is also responsible for the therapeutic and physio-
logical effects in rats,45 human VEGF165 cDNA was used for the construc-
tion of various hypoxia-inducible VEGF plasmids including pSG5-VEGF, 
pRTP801-VEGF, and pEpo-SV-VEGF. pSG5-VEGF was kindly provided 
by Jozef Dulak (Department of Cardiology, University of Innsbrook, 
Innsbrook, Austria). pRTP801-VEGF was generated by cloning the RTP801 
promoter into pSV-VEGF as previously described.16 Briefly, the human 
VEGF165 cDNA was amplified by PCR using pSG5-VEGF as a template. 
The HindIII/XbaI sites were attached at each end of the cDNA. The PCR 
product (VEGF cDNA) was inserted into the pSV-Luc vector (Promega) 
at the HindIII/XbaI sites after the deletion of the luciferase gene in order 
to construct pSV-VEGF. The RTP801 promoter was cloned using genomic 
DNA extracted from liver hepatocellular carcinoma cells with DNeasy 
Tissue kit (Qiagen, Valencia, CA). The BglII/HindIII sites were introduced 
into the RTP801 promoter. The SV40 promoter was then removed from 
pSV-VEGF and the PCR-amplified RTP801 fragment was inserted into 
the BglII/HindIII sites, to produce the pRTP801-VEGF  vector. The pEpo-
SV-VEGF vector was constructed as previously reported.18 To produce 
the pEpo-SV-VEGF vector, the erythropoietin enhancer containing the 
BamHI/XbaI sites was synthesized chemically and was inserted at a BglII 
site upstream of the SV40 minimal promoter. Construction of plasmids 
was confirmed using restriction enzyme digestion and DNA sequence 
analysis.
In vitro transfection. For in vitro transfection study, MSCs were plated at 
a density of 1.0 × 105 cells/well in a six-well plate. After 24 hours of incuba-
tion, the culture medium was exchanged with fresh serum-free medium. 
Cells were transfected with the plasmids prepared with LPEI (25 kDa) at 
a N/P ratio (nitrogen of PEI/phosphate of DNA) of 10:1 unless otherwise 
mentioned. After 4 hours of transfection, the medium was replaced with 
fresh 10% serum medium. The transfected cells were further incubated in 
hypoxic (1% oxygen, 5% CO2, 95% nitrogen) and normoxic (20%  oxygen, 
5% CO2, 75% nitrogen) conditions for 24 hours. It has been known that 
erythropoietin enhancer/SV promoter-containing plasmid vectors 
increase target gene expression 6 hours after exposure to hypoxia and 
the expression levels are rapidly recovered within 1 hour after eliminat-
ing hypoxic conditions.46 For measurement of luciferase  activity, treated 
cells were lysed using reporter lysis buffer (Luciferase Assay Kit, Promega). 
The luciferase activity in cell lysates was monitored using a SIRIUS lumi-
nometer (Berthold Detection System GmbH, Pforzheim, Germany) with 
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an integration measurement time of 20 seconds. The relative values of 
luciferase activity were expressed in terms of relative light units/mg of cell 
protein. The protein concentration of the extract was determined using a 
bicinchoninic acid protein assay kit (Pierce, Iselin, NJ). The cytotoxicity 
assay was carried out in a 24-well plate at a density of 1 × 104 MSCs/well. 
After performing the transfection process, the cells were assayed using 
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide to 
assess cell viability. The relative cell viability was calculated and expressed 
as percentage of viable cells. For VEGF plasmid transfection experiments, 
the conditioned medium was harvested at desired time intervals. The level 
of VEGF protein in the medium was measured using a human ELISA 
kit (R&D Systems, Minneapolis, MN) according to the manufacturer’s 
instructions. All of the data are presented as the mean ± standard devia-
tion (SD) of three replicate samples. In order to characterize the phenotype 
of the isolated MSCs and HI-VEGF-MSCs, cells were analyzed by flow 
cytometry after staining with fluorescence-labeled monoclonal antibod-
ies for CD34-phycoerythrin, CD45-phycoerythrin, and CD90-fluorescein 
isothiocyanate (BD Biosciences, San Diego, CA). In brief, the harvested 
cells (1 × 106 cells/ml) were incubated with antibodies (0.5 mg/ml) for 
15 minutes at room temperature and then washed twice with phosphate-
buffered saline. Fluorescent intensities of cells labeled with antibodies 
were detected using fluorescence-activated cell sorting analysis (Becton 
Dickinson, San Jose, CA).
Myocardial infarction, intramyocardial cell transplantation, and histo­
logy. Experimental myocardial infarction was induced in 8-week-old male 
Sprague–Dawley rats (240 ± 10 g) as described earlier.43 Under general anes-
thesia, the rat heart was exposed through a 2 cm incision at the left lateral 
costal rib. The LAD was ligated with a 6-0 silk suture (Ethicon, Somerville, 
NJ) for 1 hour, followed by reperfusion. Ischemia was confirmed by visual 
inspection of blanching in the myocardium distal to the site of occlusion. 
In sham-operated rats, the same procedure was performed without LAD-
ligation. For intramyocardial cell transplantation 1 hour immediately after 
the surgical occlusion, MSCs, and HI-VEGF-MSCs (2.0 × 106 cells) were 
injected in a total volume of 60 μl serum-free medium with a 30-gauge 
needle into the anterior and lateral aspects of the contracting wall border-
ing the infarct. To prepare HI-VEGF-MSCs, MSCs were transfected using 
the pEpo-SV-VEGF/LPEI formulations prepared at a N/P ratio of 10:1 and 
were further incubated for 24 hours prior to implantation. For histological 
cell tracking, MSCs were labeled with DAPI (1 μg/ml, Molecular Probes, 
Eugene, OR) for 30 minutes on the day of implantation, according to the 
manufacturer’s suggested protocol.
Four groups of animals were used: Normal (sham operation); Control 
(LAD-ligation and saline treatment); MSCs (LAD-ligation and MSC 
injection); and HI-VEGF-MSCs (LAD-ligation and HI-VEGF-MSC 
injection). To investigate the effects of infarction on in vivo VEGF production 
by HI-VEGF-MSC transplanted into myocardium, noninfarcted rats were 
also transplanted with HI-VEGF-MSCs using the same method as that 
used in the infarcted rats. Two weeks after cell transplantation, the animals 
were killed and used for histological examination. The heart tissues were 
perfusion-fixed with 10% formaldehyde, embedded in paraffin, and cut 
into 5 μm sections. Every third section was collected for further analysis. 
All histological measurements were done in a blinded manner. For 
assessment of in vivo VEGF production following cell implantation, rat 
hearts, and blood were harvested 48 hours postimplantation. The levels 
of VEGF in the heart tissue and blood extracts were analyzed by ELISA 
method according to the directions of the manufacturer. To analyze MSC 
engraftment within infarcted myocardia, DAPI-stained MSC-treated 
animals were killed 3 days after implantation. Fluorescence images were 
scanned by a fluorescence microscope (Olympus IX71, Tokyo, Japan) 
using the excitation filter G365. For immunohistochemical examination 
of human VEGF, the deparaffinized tissue sections were incubated with 
primary monoclonal antibody (antihuman VEGF, 1:100 dilution, AbCam, 
Cambridge, MA), following incubation in biotinylated pan-specific 
universal secondary antibody. The samples were further processed by a 
streptavidin/peroxidase complex method using a Vectastain Universal 
Quick Kit (Vector Laboratories), followed by 3,3-diaminobenxidine 
(Vector Laboratories) staining. The nuclei were counterstained with 
hematoxylin. The images were distinguished at ×100 magnification. For 
analysis of histological changes, all histology samples were observed 
within the infarct border zone.
Immunohistochemistry. Staining for CD31, also known as platelet 
endothelial cell adhesion molecule 1, can provide a partial measure of 
the microvasculature.43 For immunohistochemical examination of CD31, 
tissue sections were deparaffinized and subjected to antigen retrieval by 
microwave heating for 10 minutes in 10 mmol/l sodium citrate (pH 6.0).
The sections were blocked in 2.5% normal horse serum and incubated 
with 3% H2O2 in methanol to quench endogenous peroxidase activity. The 
samples were then incubated with primary monoclonal antibody (anti-
CD31, at 1:50 dilution, AbCam), followed by incubation with biotinylated 
pan-specific universal secondary antibody. The sections were then 
processed by a streptavidin/peroxidase complex method with a Vectastain 
Universal Quick Kit, followed by 3,3-diaminobenxidine staining. Nuclei 
were counterstained with methyl green. All images were generated under 
light microscopy and were processed using MetaMorph software ver 4.6 
(Universal Imaging, Downingtown, PA). The numbers of CD31-positive 
cells per square millimeter were determined by counting whole sections 
in a blinded fashion at ×100 magnification.
TUNEL assay. TUNEL assays were using the ApopTag Peroxidase In Situ 
Apoptosis Detection Kit (Chemicon International, Temecula, CA) on the 
myocardia, according the manufacturer’s instructions. A positive control 
sample was prepared from a normal heart section treated with DNase I 
(10 U/ml, 20 minutes at room temperature). Apoptotic nuclei were visu-
alized using 3,3-diaminobenxidine (Vector Laboratories). Apoptotic cells 
were counted under a light microscope. The specimens were then examined 
over a total of five HPF (×400 magnification) per slice. The value assigned to 
each specimen was the mean of these five measurements (n = 6 per group).
Fibrosis and infarct size analysis. Heart sections were stained with conven-
tional hematoxylin and eosin and Masson’s trichrome for analysis of fibro-
sis. The fibrotic area was measured with MetaMorph software ver 4.6 and 
was expressed as a percentage of the total left ventricle. For measurement of 
myocardial infarct size, hearts were sectioned transaxially and incubated in 
1% 2,3,5-triphenyltetrazolium chloride (Sigma, St Louis, MO) for 20 min-
utes at 37 °C. The tissue sections were then fixed in 10% formalin overnight 
at 2–8 °C. Heart sections were then photographed with a digital camera. 
Viable myocardium stained deep red, whereas infarct appeared yellow-
white. The areas of normal and infarcted left ventricular myocardium were 
measured with planimetry using ImageJ software from National Institutes 
of Health. The infarct size of the left ventricle was calculated as the ratio (%) 
of cumulative infarct area (infarct tissue) to the entire left ventricle area.
Assessment of cardiac function. Two-dimensional echocardiography 
was performed at baseline (normal rats) and for all operated rats (n = 6 
per group) at 2 weeks after LAD ligation by an experienced cardiologist 
blinded to the identity of the groups. Conscious rats were imaged with a 
GE Vivid Seven ultrasound machine (GE Medical System, Salt Lake City, 
UT, http://www.gehealthcare.com) with a 10.0 MHz transducer. Data were 
analyzed using digitized pictures of the short-axis views.
Statistical analysis. Data are presented as the mean ± SD. Comparisons of 
two groups were made by Student’s t-test. A P values <0.05 were considered 
statistically significant.
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